Launching Revvity: A Scientic Solutions Company Powering Innovation from Discovery to Cure
11 May 2023
Transformation aimed at revolutionizing next generation scientic breakthroughs that solve the world’s greatest health challenges
Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions
To begin trading as RVTY under new name on May 16th (formerly NYSE: PKI)
WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. ocially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, “revolutionize” (rev) and “vita” (vit) meaning “life” in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was previously aliated with PerkinElmer, Inc.
“The unveiling of Revvity is the capstone of a nearly year-long journey that has transformed who we are and reinforces why our work matters,” said Prahlad Singh, president and chief executive ocer of Revvity. “At Revvity, we are united with our customers to impact health across the lifespan. Our purpose is to expand the boundaries of human potential through science. We view the challenges facing our customers as a call to action.”
Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech, diagnostic labs, academia and government agencies. “We’re a translational company in the sense that our capabilities facilitate decision making between research and clinical customers,” remarked Singh. “With cross-business collaborations between our automation, multi-omics oerings, and our Signals software 1 business, we have unique capabilities which put us in an optimal position to accelerate breakthrough solutions – starting with preclinical research and scientic discovery, all the way through to diagnosing and helping to treat disease.”
Changes to Brand Architecture
Industry leading franchises, BioLegend, EUROIMMUN, Tulip Diagnostics and ViaCord retain their own names as unique product lines.
The Company’s comprehensive scientic software platform, previously known as PerkinElmer Informatics, will become
Revvity Signals Software, Inc. Revvity Omics replaces PerkinElmer Genomics as the Company's genomics services business.
Cisbio, Horizon Discovery, Nexcelom Bioscience, Omni International, Oxford Immunotec, SIRION Biotech and SonoVol will now identify as Revvity, while maintaining their specic product names.
Visit the “Our Story” page for more on the Company’s evolution and download the corporate fact sheet to get a full list of facts and gures.
What’s ahead?
Revvity’s Q1 earnings webcast is scheduled on May 11, 2023 at 8:00 a.m. ET. Register here.
The Company will trade under its new name and the stock ticker symbol "RVTY” at market open on May 16, 2023. At the same time its 1.875% Notes due 2026 will begin trading under “RVTY 26.” Members of the Revvity team will commemorate the new name, brand and stock ticker by ringing the bell that morning at the New York Stock Exchange. A livestream of the ceremony can be viewed here.
Roadshows intended for existing and prospective customers will be scheduled in select global markets to introduce the new brand and latest innovations. Follow Revvity’s social media channels for updates.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash ow and revenue growth and other nancial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," “estimates,” "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to dier materially from the results described, implied or projected in any 2 forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the eect of the COVID-19 pandemic on our sales and operations; (3) uctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them protable, or successfully divest businesses; (6) our ability to compete eectively; (7) uctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) signicant disruption in third-party package delivery and import/export services or signicant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) signicant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future nancing; (21) restrictions in our credit agreements; (22) signicant uctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other lings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identication, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, Twitter, YouTube, Facebook and Instagram for updates.
Investor Relations:
Steve Willoughby
(781) 663-5677 3
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com
Source: Revvity, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.